Dr. Lydon is a co-founder of AnaptysBio and won the 2009 Lasker-DeBakey Clinical Medical Research Award along with two other scientists for the development of Gleevec® (imatinib), a molecularly-targeted treatment for chronic myeloid leukemia, which converted a fatal cancer into a manageable chronic condition. Dr. Lydon holds a doctorate in biochemistry from University of Dundee, Scotland, and has previously served as vice president, small molecule drug discovery at Amgen, Inc. Prior to joining Amgen, Dr. Lydon was the founder, CEO and president of Kinetix, Inc., a biotech company focused on the development of selective protein kinase inhibitors.
Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies. AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity. AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Health
|SOURCE AnaptysBio, Inc.|
Copyright©2010 PR Newswire.
All rights reserved